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Phagocytosis in uremic and hemodialysis patients: A prospective and 
cross sectional study. Leukocyte response to phagocytic challenge was 
assessed in uremic and hemodialysis patients in a prospective and cross 
sectional study. Using latex, zymosan and staphylococcus as phago-
cytic challenge, the utilization of glucose-I-Ct4 and the generation of 
reactive oxygen species was measured in these patients. In uremic, 
non-dialysis dependent patients, the response to phagocytosis was 
significantly reduced when creatinine exceeded 6 mg/dl and prior to 
initiation of dialysis (mean serum creatinine 9.3 ± 0.3 mg/dl) was less 
than half that of patients with normal renal function (P < 0.01). In a 
prospective study of 15 patients initiated on dialysis,the metabolic 
response of their leukocytes was assessed sequentially. In eight pa-
tients, initiation of dialysis with cuprophane (Cu) membrane lead to a 
further decline (60%) in their metabolic response to phagocytosis at the 
end of four weeks of dialysis compared to pre-initiation of dialysis (P < 
0.01), whereas in seven other patients, dialysis with non-complement 
activating membranes did not result in a significant decline. Prospective 
cross-over studies of chroniC hemodialysis patients corroborated these 
findings: eight patients dialyzed with new CU membranes had a 
significant decline of their metabolic response to phagocytic challenge 
acutely at the end of each dialysis and in pre-dialysis samples after two 
weeks of Cu dialysis, whereas their,response returned back to baseline 
after two weeks of dialysis with non-complement activating membrane. 
In prospective and cross sectional studies, a decreased response to 
phagocytic stimulus was a predictor of hospitalization, primarily for 
infectious reasons. We conclude that both uremia and the type of 
dialysis membrane affect the ability of leukocytes to respond to 
phagocytic challenge, and that the risk of infections increases with 
advancing uremia and is worsened with the use of eu membrane. 
Bacterial infections and sepsis remain important causes of 
morbidity and mortality in the end-stage renal disease (ESRD) 
patients [1-4]. Although this outcome is impacted upon by 
several factors, phagocytosis by polymorphonuclear leukocytes 
(PMNL) and monocytes, so called phagocytes, constitutes a 
critical mechanism of host defense against infections [5-9]. 
Several studies have examined the process of phagocytosis in 
uremia and the results of these studies have been conflicting [2, 
7]. A recent comprehensive review on the subject concluded 
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that "it is difficult to derive any firm conclusions from this wide 
variety of findings" [7]. 
A possible explanation for these different results may lie in 
the different methodologies used, different patient popUlations 
with little attention paid to the duration or other parameters of 
the dialysis treatment. In addition, few clinical studies have 
addressed the potential role of the dialysis membrane on 
phagocytosis [10, 11]. In the present study, we therefore 
determined the metabolic response of PMNL's [12-15] to 
different phagocytic stimuli [latex, zymosan, Staphylococcus 
Aureus (Staph. A.)] in uremic (non-dialyzed) and dialysis pa-
tients in a prospective cross-over study design, as well as in a 
cross sectional study of patients on hemodialysis. 
Several metabolic pathways are activated during phagocyto-
sis and their measurement may be taken as a reflection of the 
functional capacity of these phagocytes. These pathways in-
clude the metabolism of glucose through the hexosemonophos-
phate shunt (HMS) pathway, as well as the production of 
reactive oxygen species (ROS), including superoxide ions and 
hydrogen peroxide (H20 2 ) via the NADPH oxidase system [9, 
13-16]. As shown in Figure 1, these two processes are interre-
lated since the HMS pathway provides the energy for the 
formation of the ROS via the NADPH oxidase enzyme [17]. 
In this study, we used the assessment of both pathways 
independently to study the phagocytic ability of PMNL's. 
Although the phagocytic response involves monocytes as well 
as neutrophils, the general term leukocytes (PMNL) will be 
used in the text. Specifically we used the assessment of glucose 
metabolism for the determination of the effects of uremia as 
well as the prospective effects of initiation of dialysis with two 
membranes of different biocompatibilities [18]. In addition, we 
used the measurement of the intracellular production of reac-
tive oxygen species to study the effects of these membranes on 
the phagocytic response of PMNL's of chronically dialyzed 
patients. 
We investigated the hypothesis that recurrent complement 
and leukocyte activation as occurs during cuprophane mem-
brane dialysis leads to an acute as well as chronic decrease in 
the response of leukocytes to phagocytic stimuli [19], and that 
this adverse effect is independent and superimposed on the 
effects of uremia [1,12]. Using these different methods for the 
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assessment of phagocytic response, the results of our study 
confirm this hypothesis. 
Methods 
All patients participating in this study gave informed consent 
approved by their respective hospital's Institutional Review 
Boards. Exclusion criteria included patients with diabetes, 
history of malignancy or hematologic or liver diseases, or with 
active or recent infections documented by hospitalizations, 
leukocytosis or fever greater than lOO°F (3SSC) in the past 
three months. Patients on medications such as antibiotics, 
corticosteroids or immunosuppressive medications were like-
wise excluded from consideration. All patients were started on 
1,25 vitamin D3 (generally 0.25 JLg per day) when their creati-
nine exceeded approximately 4 to 5 mg/dl, and were maintained 
on it throughout their treatments. 
The dialysis membranes studied included cuprophane as a 
reference membrane (Bravo 501 and Gambro GF-120; both of 
these manufacturers use cuprophane membrane from the same 
supplier, ENKA, Germany). This was compared to synthetic 
membranes with minimal complement and/or leukocyte activa-
tion capabilities. These consisted of either the low-flux polysul-
fone (F-6, Fresenius, Germany), or the polymethylmethacrylate 
(PMMA; Toray B2 1.5H, Tokyo, Japan). All dialyses were 
performed with bicarbonate dialysate. 
Materials 
Cross sectional study. To study the potential effects of 
increasing uremia, 116 patients with chronic renal failure and 
with various levels of serum creatinine were selected for study. 
The range of creatinine was from 2.0 mg/dl to > S mg/dl. Fifty 
patients with serum creatinine determinations of::5 1.3 mg/dl 
and creatinine clearance of greater than SO mVmin were selected 
as controls. Patients were studied one time only; atthe time of 
blood sampling for the estimation of phagocyte metabolism, 
bloods for routine biochemical and hematological determina-
tions were drawn concurrently. 
In a similar cross-sectional study, the metabolic response to 
phagocytosis of 50 chronic hemodialysis patients with varying 
times on dialysis, (0.5 to 13 years) was investigated . Patients 
studied were on the same membrane and with the same dialytic 
prescription for the prior three months. However, different 
patients were dialyzed with different membranes and with 
different reuse procedures. All samples in this cross-sectional 
study were obtained pre-dialysis, at the time of their monthly 
biochemical and hematological evaluation. 
Fig. 1. The metabolic pathways of leukocyte 
activation using the NADPH oxidase enzyme. 
Prospective study: (a) Chronic renal failure patients (prior to 
dialysis). Thirty-two patients with chronic renal failure were 
studied prospectively prior to the initiation of dialysis. The 
mean creatinine clearance of these patients at the start of the 
study was IS mVmin. After an observation period of S.9 ± 0.9 
months, IS of these patients required initiation of dialysis: eight 
were initiated and maintained on dialysis using cuprophane 
hollow-fiber membrane and seven patients were initiated on 
dialysis using polysulfone hollow-fiber dialyzer. The choice of 
the dialyzer membrane was random. No reuse was carried out 
in this part of the study. The evaluation of the response of 
PMNL's to phagocytic stimuli was carried out once a week 
pre-dialysis during the first four weeks, and subsequently once 
every four weeks until approximately 12 weeks after initiation 
of dialysis. At each evaluation point, a complete blood count 
(CBC) and differential was also obtained to determine the 
number of PMNL's platelets and hematocrit. 
(b) Chronic dialysis patients . Eight chronic, stable hemodi-
alysis patients were studied. Four of these patients were 
chronically dialyzed with a cuprophane membrane in a facility 
practicing reuse with bleach and formaldehyde. The use of 
bleach, which degrades the protein surface on these mem-
branes, restores the ability of the cuprophane surfaces to 
activate complement [20]. In that regard therefore, these mem-
branes are equivalent in their complement activating ability to 
new membranes. During the initial two weeks of the study, 
these patients were dialyzed with the PMMA membrane (Toray 
B2-l.SH), a non-complement activating (low flux) membrane 
[1S]. During the subsequent two weeks, the patients were 
dialyzed with a new cuprophane membrane dialyzer during 
each dialysis. Four other patients who were chronically dia-
lyzed with polysulfone membrane dialyzers (Fresenius F-60), a 
high-flux membrane that is also not associated with complement 
activation, were initially placed on new cuprophane membranes 
for two weeks and then switched to dialysis with PMMA 
membranes for the next two weeks. 
At the beginning and end of each two weeks, blood samples 
were drawn from the afferent end of the dialyzer at pre-dialysis, 
and at three hours after initiation of dialysis and analyzed for 
their ability to generate ROS in response to Staph. A as outlined 
below in Methods. 
In an effort to validate the different methodologies used, we 
also examined the intradialytic glucose-I-C 14 utilizatioQ by 
PMNL's in response to Staph. A particles, in eight chronic 
hemodialysis patients while on new cuprophane membrane 
dialysis. 
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Methods 
Glucose-I-Cf4 uptake. The principle of the assay for the 
determination of glucose uptake is based on the glycolytic 
pathway in leukocytes and monocytes as shown schematically 
in Figure I. In brief, the determination of glycolysis was done 
by measuring 14C02 generated from the metabolism of glucose-
1_ 14C by the HMS pathway, with and without incubation with 
latex, zymosan or Staph. A. particles as phagocytic challenges. 
Using sterile conditions, 50 ILl of heparinized blood was 
mixed immediately after withdrawal with 10 ILl of a solution of 
glucose-I-14C (Amersham, London, UK) containing 0.5 ILg of 
glucose per 10 ILl in a capped sterile tube (Packard Instruments, 
Down Grove, Illinois, USA) in a constant temperature 37°C 
shaker. Incubation was allowed to proceed for one hour. 
Further metabolism was arrested by cooling the tube to -20°C. 
The amount of 14C02 evolved in response to this challenge was 
continuously trapped by a filter containjng 100 ILl of 1 N NaOH. 
For baseline studies, no additional stimulus was added, 
whereas the glycolytic activity in response to phagocytic chal-
lenge was evaluated by thfe addition of latex or zymosan 
particles as described below. At the end of the procedure, the 
NaOH impregnated filter was then removed and the 14C02 
measured in a Beta counter and expressed as Disintergrations 
Per Minute (DPM) and adjusted for the number (in thousands) 
of PMNL determined separately by a CBC. All analyses were 
performed in triplicate and all baseline and stimulated samples 
were processed simultaneously and in parallel. The results of 
this part of the study are reported as ADPM/103 PMNL, which 
represents the difference in DPM (adjusted for cell count) 
between the baseline sample and DPM of samples after incu-
bation with the specific stimulus. 
Latex (Difco, Detroit, Michigan, USA) was prepared in a 
stock solution of approximately 2.5 x 109 particles (0.8 IL)/ml, 
whereas zymosan (Sigma Chemical Co., St. Louis, Missouri, 
USA) was prepared as a stock solution of 5 g/100 ml in AB 
serum, also resulting in approximately 2.5 x 109 particles/mUn 
preliminary studies, optimal concentrations and time depen-
dence was determined for both agonists by the maximum 
change in DPM between baseline and stimulated samples. The 
optimal concentrations were I PMNL to approximately 100 
latex particles and 1 PMNL to 100 zymosan particles. At these 
concentrations, the 14C02 production was increased four- to 
eightfold from baseline and was less sensitive to minor varia-
tions in the PMNL to agonist ratio. The volume of the agonists 
was therefore adjusted to be as close as possible to these ratios, 
depending on the leukocyte count. 
Similarly, the optimum time for incubation was determined 
by the change in DPM for latex particles and zymosan sepa-
rately as a function of time. For latex particles,llDPM reached 
a plateau at around 60 minutes whereas for zymosan, a plateau 
was not reached until 120 minutes, but the rate of change was 
considerably slower at around one hour. For the sake of 
uniformity, all values of DPM were measured at one hour 
following addition of the agonist. 
We also determined that the utilization of glucose-l-14C was 
unaffected by changes in the serum concentration of sodium 
(range: 120 to 160 mEq/liter), glucose (100 to 300 mg/dl) , 
calcium (range: 8 to 12 mg/dI), pH (range: 7.0 to 7.6), potassium 
(range: 2 to 6 mEq/liter) and phosphorus (range: 2 to 7 mg/dl: 
(data not shown). 
Since erythrocytes can utilize glucose in the same metabolic 
pathway (HMS), we performed additional experiments to define 
the contribution of RBC's to glucose-l-14C utilization. The 
production of 14C02 was linearly related to hematocrit, and in 
the unchallenged ("resting state") sample, accounted for ap· 
proximately 40% of the glucose-I-CI4 utilization. However, 
there was no difference in the utilization of glucose-l-C 14 by 
"resting" RBC's and those incubated with either latex or 
zymosan. Since measurement of phagocytic response is re-
ported as changes in DPM (IlDPM) calculated from the differ-
ence in DPM response with and without the agonist, changes in 
hematocrit did not affect the results. 
Reactive oxygen production by PMNL. Blood samples were 
immediately placed on ice and leukocytes isolated using Dex-
tran sedimentation at 4°C, followed by hypotonic lysis [21]. 
This method of separation avoids the use of density gradient 
centrifugation which may select PMNL's of specific density. 
Subsequently the cells were diluted to a concentration of 1 x 
106 cells/ILl using tris buffer adjusted to pH of 7.3 and containing 
1.2 mM CaCl2 and 1.0 mM MgCI2 • The phagocytic ability was 
monitored using the fluorescence of dichlorofluorescein-diace-
tate (DCF-DA; Kodak, Rochester, New York, USA), a mole-
cule which becomes fluorescent once acted upon by reactive 
oxygen species [22], a metabolic product of the respiratory 
burst that PMNL's generate in response to phagocytosis [5, 12, 
13]. In detail, once the leukocytes were isolated, they were 
incubated with 5 ILM DCF-DA for 15 minutes at 37°C in a 
shaking water bath to allow diffusion inside the cells. These 
cells were then incubated with staphylococcus aureus (wood 
strain; Sigma) previously opsonized in AB sera at a temperature 
of 37°C for 45 minutes in a shaking water bath. The ratio of the 
staphylococcus to PMNL was approximately 20 organisms for 
each cell. 
Green and red fluorescence analyses were performed on a 
flow cytometer (EPICS 753, Coulter, Hileah, Florida, USA) 
with argon laser. Fluorescence was standardized each day by 
fluorescent microbeads and voltage, amplification and compen-
sation kept constant for all procedures. Analysis was performed 
on 3,000 viable leukocytes separated according to size and 
granularity. Positive controls were cells incubated with 100 
lLg/ml Phorbol myristate acetate (Sigma) (PMA), a powerful 
activator of protein kinase C and of leukocyte metabolic path-
ways. Cells incubated with DCF-DA only, with no agonist, but 
treated in exactly the same way served as negative control. 
Mean fluorescence was displayed logarithmically and the mean 
log fluorescence was noted. As seen in Figure 2, leukocyte 
preparations incubated with Staph. A had a significantly higher 
fluorescence than controls and their fluorescence was not 
significantly different from PMA incubated cells. In addition, 
fluorescence response reached a pleateau after 45 minutes of 
incubation. 
Ingestion of bacteria by fluorescent cells was verified by a 
fluorescent light microscopy which also indicated the absence 
of fluorescence by leukocytes that had not undergone phagocy-
tosis. In addition, Texas-red fluorescein coated bacteria (Accu-
rate, New York, USA) were incubated with DCF-DA loaded 
leukocytes and the red and green fluoresence, monitored simul-
taneously. The majority of the cells that had the Texas-red 
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Fig. 2. The fluorescence response of DCF-DA loaded leukocytes in 
response to PMA (0) at a concentration of 100 jJ-glml, Staph Aureus 
(cells to organism ratio 1:20) (e), and controls (1::,.) as a function of 
incubation time at 37"C. 
Table 1. 
Serum creatinine Creatinine 
mgldl dDPM/I03 PMNL 
clearance 
Group Range Mean mllmin Latex Zymosan 
A (N = 50) <1.3 0.9 ± 0.1 107 ± 7 154 ± 7 339 ± 15 
B (N = 35) 1.3-1.9 1.6 ± O.lb 56 ± 3b 140 ± 11 339 ± 23 
C (N = 21) 2.0-2.9 2.4 ± O.lb 40 ± 3b 124 ± 13 318 ± 26 
D (N = 12) 3.0-3.9 3.6 ± O.lb 21 ± 2b 131 ± 14 349 ± 33 
E (N = 17) 4.0-5.9 4.9 ± 0.2b 16 ± 2b 134 ± 7 360 ± 15 
F (N = 16) 6.0-7.9 7.1 ± 0.2b 11 ± Ib 102 ± 7" 268 ± 21 a 
G (N = 15) > = 8.0 9.3 ± 0.3b 8 ± Ie 70 ± 8e 183 ± 1ge 
a P < 0.05, b P < 0.01, e P < 0.001 vs. A 
fluorescence also had the green DCF fluorescence, indicating 
the validity of this test for the determination of phagocytosis of 
Staphylococcus Aureus particles by PMNL's. 
Statistics 
Results are expressed as means ± SEM. Statistical analysis of 
data for intradialytic changes were performed by variance 
analysis (ANOV A). Data between different dialyzers and be-
tween different groups of patients were first analyzed using 
variance analysis and when statistical significance was reached, 
the remaining sets of data were further submitted to Wilcoxon's 
test for paired and unpaired values. The correlation regression 
analysis was performed by Spearman's test. Statistical signifi-
cance was accepted for P < 0.05. 
Results 
Cross sectional studies 
The change of glucose metabolism by PMNL in response to 
latex and zymosan in patients with chronic renal failure is 
shown in Table 1. When grouped by narrow ranges in their 
serum creatinine, patients had no statistically significant 
changes in their response to either latex or zymosan until serum 
creatinine level exceeded 6 mg/dl (mean creatinine for the group 
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Fig. 3. Glucose-I-C'4 utilization by PMNL expressed as ddisintegra-
tion per minutes per ](/ PMNL in response to latex (A) and zymosan 
(B) for normal controls (C) and patients on chronic hemodialysis (H). 
Mean values for dialysis patients was significantly less (**P < 0.01) 
than controls. 
7.1 ± 0.2 mg/d\). At this level of renal failure, the metabolic 
response to phagocytic stimuli by either latex or zymosan was 
significantly reduced and in the group of patients with creatinine 
over 8 mg/dl (mean = 9.3 ± 0.3 mg/d\), the metabolic response 
was reduced to half the value for normals (Table O. In addition, 
there was a linear negative correlation between the ~DPM for 
both latex and zymosan and the level of creatinine (and a 
positive correlation with creatinine clearance) for creatinine 
values above 4 mg/dl. For zymosan particles, the correlation 
can be expressed as ~DPMzymosan = 505-33 x creatinine 
(mg/d\), N = 48, r = -0.63, P < 0.001), whereas for latex, the 
correlation can be expressed as ~DPMlatex = 185-12 x creati-
nine (mg/d\), N = 48, r = - 0.58, P < 0.001). 
Similarly, the metabolic response to phagocytic stimuli was 
evaluated in 50 hemodialysis patients at the beginning of a 
dialysis session selected at random. The change in ~DPM for 
latex and zymosan is illustrated in Figure 3, along with an age 
and sex matched control group of 50 individuals with normal 
renal function tested concurrently. Although there was overlap 
in the ~DPM response between hemodialysis patients and 
controls for both latex and zymosan, the mean value of hemo-
dialysis dependent patients (78.4 ± 5.3 for latex and 172.0 ± 
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12.8 for zymosan) was significantly less (approximately half) 
than controls for both agonists (P < 0.01). There was no 
statistically significant correlation between the value of 
aDPMlatex or aDPMzymosan with age, sex, primary renal diag-
nosis or the dose of dialysis (KTIV) used. 
At the time their metabolic response to latex or zymosan was 
determined, none of the patients had any evidence of infection. 
However, of these 50 hemodialysis patients, 15 were admitted 
to the hospital for an infectious reason (9 with positive blood 
cultures and of those four were admitted to the leu with 
evidence of hemodynamic instability) over the course of the 
following six months. Retrospective analysis of the metabolic 
response of the patients admitted to the hospital with those who 
remained unhospitalized indicated a significant difference in 
their prior response to phagocytic challenge both by latex and 
by zymosan. Thus, the 15 patients admitted to the hospital had 
aDPMzymosan response of 115 ± 21 DPM/103 PMNL, whereas 
the aDPMzymosan response for 35 patients not admitted to the 
hospital was 194 ± 14 DPM/103 PMNL (P < 0.001). Similarly, 
using latex as the challenge, the 15 patients admitted for 
infectious reasons had aDPMlatex of 63.6 ± 10.3 DPM/103 
PMNL at the time of testing whereas for the other 35 patients 
tested at approximately the same time. aDPMlatex was 
84.7 ± 6.0 DPM/103 PMNL (P < 0.05). 
Prospective study. The deterioration in the metabolic re-
sponse of PMNL with increasing levels of uremia was further 
confirmed by prospective studies of patients with progressive 
renal failure. In a group of 15 patients with progressive renal 
failure, the rise in creatinine from 5.3 ± 0.4 mg/dl to 8.8 ± 0.7 
mg/dl over a period of 5.9 ± 0.9 months was associated with a 
40% decrease in the aDPM for both latex and zymosan ago-
nists. Of interest is that in 17 patients who were followed in a 
similar time period, but with minimal change in their creatinine, 
there were no changes in their aDPM for either latex or 
zymosan (Fig. 4). 
The fifteen patients with progressive renal failure were initi-
s E 
Fig. 4. Glucose-I-CI4 utilization by PMNL 
expressed as fl.disintegration per minutes per 
](? PMNL in response to latex (A) and 
zymosan (B), for normal controls (C), and 
patients with progressive renal failure (-) and 
non-progressive renal failure (---) at the start 
(S) and end of study (E), over a period of 5.9 
± 0.9 months. (*P < 0.05, **P < 0.01 
compared to beginning of study and controls). 
ated on hemodialysis during the period of the study. A group of 
eight patients was initiated and maintained on hemodialysis 
using new (unreused) cuprophane membrane, while another 
group of eight patients was initiated and maintained on the 
poly sulfone membrane dialyzers. The metabolic responses of 
both groups of patients to incubation with latex or zymosan was 
followed prospectively in pre-dialysis samples. As can be seen 
in Figure 5, all patients initiating hemodialysis had a transient 
decrease in their metabolic response to phagocytic stimuli that 
reached a nadir approximately two to three weeks after initia-
tion of dialysis. Although this was evident for patients dialyzing 
with both types of membranes, patients dialyzed with the 
cuprophane membrane had a more profound deterioration in 
their phagocytic response than patients dialyzed with the syn-
thetic membranes which was statistically significant at most 
time points during the 12 weeks of the study. Thus, at the end 
of 12 weeks of dialysis with cuprophane membrane, the meta-
bolic response to both latex and zymosan of pre-dialysis sam-
ples had decreased by approximately 37% and 29%, respec-
tively, of the starting value (P < 0.001), whereas for the 
synthetic membrane, the decrease was less (12% for latex and 
4% for zymosan P = NS) at similar time intervals following 
initiation of dialysis. 
All 15 patients initiating dialysis during this study period were 
followed prospectively for clinical evidence of septicemia re-
quiring hospitalizations. Of the eight patients initiated and 
maintained on cuprophane membrane, three developed an 
episode of sepsis over a follow-up period of 20 weeks. On the 
other hand, none of the patients dialyzed with synthetic mem-
branes had an episode of sepsis over the same time frame. This 
difference was close to statistical significance by chi-square 
analysis (P = 0.07). 
The reactive oxygen response of isolated leukocytes to 
incubation with staphylococcus aureus particles in eight 
chronic hemodialysis patients studied prospectively confirmed 
the general conclusions outlined above. 
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Fig. 5. Glucose-I-C I4 utilization by PMNL expressed as !ldisintegration per minutes per Ht PMNL in response to latex (A) and zymosan (8)for 
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hemodialysis. *P < 0.05, **P < 0.01 from initiation of dialyses. The difference between both groups was statistically significant at all time points 
(except the 2nd week for !lDPMzymosan)' 
Thus, the fluorescence of leukocytes harvested from all 
patients dialyzed with new cuprophane membrane was signifi-
cantly worse in samples obtained after three hours of dialysis 
when compared to leukocytes isolated from pre-dialysis sam-
ples (166.3 ± 6.5 log fluorescence units pre-dialysis to 115.0 ± 
9.7 log fluorescence units 3 hours after dialysis, P < 0.01). In 
sharp contrast, intradialytic changes with the synthetic PMMA 
membrane showed a modest improvement (from 147.5 ± 7.9 log 
fluorescence units pre-dialysis to 158 ± 8.3 log fluorescence 
units at the end of dialysis) in their response to Staph A 
challenge. 
The impact of cuprophane membrane was, however, most 
evident after two weeks of recurrent exposure of patients to this 
membrane, even in pre-dialysis samples. Thus, leukocytes 
harvested pre-dialysis at the end of two weeks of Cu dialysis 
decreased to 127.9 ± 7.8 (P < 0.01) compared to pre-dialysis 
samples at the beginning of the Cu phase. When these patients 
were subsequently dialyzed for two weeks with PMMA mem-
branes, fluorescence response to staphylococcus increased 
from 147.5 ± 7.9 to 178 ± 8.3 log units, (P < 0.001). 
The decrease in the metabolic response of isolated PMNL to 
Staph A seen by cell flow cytometry in patients dialyzed with 
cuprophane membrane, was also evident when glucose-l-CI4 
was measured intradialytically using the methods outlined in 
response to Staph A. Thus, at 15 minutes .£lDPM of PMNL in 
response to Staph A. decreased by 90% of pre-dialysis values 
and at 240 minutes was still significantly reduced compared to 
pre-dialysis samples (Fig. 6) in spite of normalization of the 
count to the number of circulating PMNL. This intradialytic 
decline must be judged in the context of an already reduced 
phagocytic response of pre-dialysis samples as compared to 
normal controls. Thus, while the mean !lDPM/103 PMNL 
pre-dialysis was 123.3 ± 10.2/103 PMNL, the .£lDPM of seven 
normal individuals against the same concentration of Staph A 
was 262.4 ± 7.1 (P < 0.001). 
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Fig. 6. lntradialytic changes in the glucose-I-C14 utilization by PMNL 
during dialysis with cuprophane membrane. There was a sharp de-
crease in the glucose utilization in response to Staph A in leukocytes 
harvested at 15 minutes (P < 0.001) which persisted at 240 minutes (P 
< 0.01). **p < 0.001, *P < 0.05. 
Discussion 
The results of this study are consistent with the hypothesis 
that the metabolic response to phagocytosis worsens with 
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progression of uremia, and is further adversely affected by the 
initiation and maintenance of patients on membranes such as 
cuprophane that lead to recurrent activation of several inflam-
matory response pathways [23]. In two groups of hemodialysis 
patients, followed prospectively, the decrease in metabolic 
response to phagocytosis was predictive of subsequent hospi-
talization episodes for infectious reasons. 
The results of this study are in agreement with other studies, 
studies which have documented the "deactivation" of leuko-
cytes following complement activation [24-27]; other studies 
have also shown that there was a significant impairment of 
stimulated oxygen consumption, glucose uptake and lactate 
production in uremic leukocytes in response to either zymosan 
or PMA as stimuli [5, 28], and decreased phagocytic ability of 
PMNL's from hemodialysis patients whether the stimulus was 
bacterial or candidal organisms [29, 30]. However. these studies 
as well as others were not prospective studies and did not 
attempt to define the separate role of uremia, initiation of 
dialysis or the dialysis membrane. 
The exact defect in this blunted response to phagocytosis 
cannot be clearly defined in this study. The metabolic response 
to phagocytosis is a global measurement of several discrete 
processes from surface expression of receptors to the specific 
agonist (such as, Fc receptors for opsonized staphylococcus or 
IgG-coated autologous red cells) to ingestion by pinocytosis and 
activation and release of several bactericidal enzymes [31-35]. 
The present study did not differentiate the specific defect in this 
global response to phagocytosis. Nevertheless, the fact that the 
defect is well delineated in response to three different particles 
(latex. zymosan and staphylococcus), is likely to be consistent 
with the fact that the primary defect does not reside solely in the 
ability of these phagocytes to express specific receptors for 
adhesion. although recent studies have clearly implicated the 
impaired function of the Fe receptors in uremics [36]. Thus, it is 
likely that the metabolic response of phagocytes to the presence 
of these particles intracellularly remains the major defect in the 
disturbed phagocytosis of uremic leukocytes. Since both the 
glycolytic pathways and the reactive oxygen production path-
way have been shown to be defective in this study, it is possible 
that this defect resides in the NADPH oxidase enzyme of 
phagocytes [31]. It is interesting to note that the level of 
response of PMNL to Phorbol myristate and bacteria in uremic 
patients is similar to carriers of chronic granulomatous disease 
(CGD) , a disease associated with a defect in the NADPH 
oxidase system, whereas those determined for patients during 
dialysis with cuprophane membrane is similar to patients with 
the fully expressed CGD disease [31, 37-39]; both patient 
populations are particularly sensitive to infections by catalase 
positive organisms such as staphylococci and enterobacteria. 
Our study has also shown that in non-dialyzed chronic renal 
failure patients, accumulation of uremic metabolites with pro-
gression of renal failure may well be a non-specific but never-
theless powerful depressant of phagocytic function. 
Despite the improvement in the concentration of small mo-
lecular weight toxins with initiation of dialysis, the metabolic 
response of phagocytes worsened considerably during dialysis 
with cuprophane membranes (and did not improve in patients 
dialyzed with non-complement activating membranes). It is 
possible that recurrent complement activation and the subse-
quent activation of leukocytes with release of their intracellular 
enzymes plays a role in the intra- and interdialytic decrease of 
their response to further challenge, similar to the studies of 
phagocytosis of bacteremic [35], trauma [40]' or burn patients 
[41]. Of note is that in dialysis patients this decrease occurs at 
a time when multiple factors. such as breakdown of skin 
integrity by needle insertion, or exposure of blood to potentially 
contaminated surfaces is on-going. 
Our study also highlights the deterioration of phagocytic 
response in pre-dialysis samples taken from patients on chronic 
dialysis with cuprophane membranes. This may be due to the 
fact that a substantial number of these leukocytes have been 
activated intradialytically and are not able to respond as well to 
further stimuli, and possibly to the egress of immature cells 
from the bone marrow during the leukocytosis that occurs with 
cuprophane dialysis. 
In summary, patients with chronic renal failure develop 
worsening metabolic response to phagocytosis that is markedly 
exacerbated by initiation or maintenance of dialysis with cu-
prophane membrane and is partly reversible with the use of a 
non-complement activating membrane. The decreased meta-
bolic response was predictive of a higher incidence of infection 
in these patients. Understanding the impact of these new 
elements. may help in the determination of the appropriate 
dialysis regimen for patients on hemodialysis. 
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